ACE inhibitor–diuretic change on renal function and qol in heart failure patients with hypertension at Tasikmalaya heart hospital

Anis Riyanti; Dichy Nuryadin Zain; Anisa Pebiansyah

doi:10.35814/jifi.v24i2.2187

Authors

Anis Riyanti Department of Pharmacy, Faculty of Pharmacy, Universitas Bakti Tunas Husada, Tasikmalaya, 46196, Indonesia
Dichy Nuryadin Zain Department of Pharmacy, Faculty of Pharmacy, Universitas Bakti Tunas Husada, Tasikmalaya, 46196, Indonesia
Anisa Pebiansyah Department of Pharmacy, Faculty of Pharmacy, Universitas Bakti Tunas Husada, Tasikmalaya, 46196, Indonesia

DOI:

https://doi.org/10.35814/jifi.v24i2.2187

Keywords:

ACE inhibitors, diuretics, kidney function, heart failure, quality of life

Abstract

Hypertension is a major contributor to heart failure and requires effective treatment to prevent clinical deterioration. Combination therapy with an ACE inhibitor and a diuretic is commonly used to control blood pressure and reduce congestive symptoms; however, renal function and quality of life need to be monitored. This study aimed to evaluate changes in renal function, describe quality of life, and analyze the relationship between renal function changes and quality of life in hypertensive patients with heart failure receiving ACE inhibitor and diuretic combination therapy. This observational study used retrospective and cross-sectional approaches. A total of 65 outpatients at Tasikmalaya City Heart Hospital from January to March 2026 were selected using total sampling. Renal function data, including urea, creatinine, and eGFR, were obtained from medical records, while quality of life was assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The Wilcoxon test showed significant changes in renal function after therapy, indicated by increased creatinine and urea levels and decreased eGFR, with p<0.05. Most patients had moderate quality of life, accounting for 60 patients (92%). Correlation analysis showed no significant relationship between changes in creatinine, urea, or eGFR and quality of life. This study indicates that ACE inhibitor and diuretic combination therapy is associated with renal function changes, but these changes are not significantly related to patients’ quality of life.

References

[1] WHO. 2025. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension. cited 2026 Jul 10.

[2] K. RI, Buku Pedoman Hipertensi di Fasilitas Kesehatan Tingkat Pertama. Jakarta: Kementerian Kesehatan Republik Indonesia, 2024.

[3] M. Nurhidayah, A. J. Saleh, and D. W. Astuti, “Asupan Natrium dan Stres sebagai Faktor Risiko Hipertensi pada Pasien Rawat Jalan di Puskesmas Talang Jawa,” J. Kesehat. Cendikia Jenius, vol. 1, no. 2, pp. 2–7, 2024.

[4] X. Huang, L. Hu, Z. Long, X. Wang, J. Wu, and J. Cai, “Hypertensive Heart Disease: Mechanisms, Diagnosis and Treatment,” Rev. Cardiovasc. Med., vol. 25, no. 3, 2024, doi: 10.31083/j.rcm2503093.

[5] M. Susanti, R. Y. Triyana, and Nurwiyeni, “Penyuluhan Dan Sosıalısası Hıpertensı Pada Lansıa Dı Aur Kunıng Bukıttınggı Sumatera Barat,” J. Abdimas Saintika, vol. 5, no. 2, pp. 25–29, 2023, [Online]. Available: https://jurnal.syedzasaintika.ac.id

[6] G. Gallo and C. Savoia, “Hypertension and Heart Failure: From Pathophysiology to Treatment,” Int. J. Mol. Sci., vol. 25, no. 12, 2024, doi: 10.3390/ijms25126661.

[7] S. Anita and Indrawati, “Hubungan Kepatuhan Mınum Obat Hıpertensı Dengan Perubahan Tekanan Darah Pada Lansıa Dı Posyandu Lansıa,” J. Keperawatan, vol. 1, pp. 52–61, 2024.

[8] B. Shahim, C. J. Kapelios, G. Savarese, and L. H. Lund, “Global Public Health Burden of Heart Failure: An Updated Review,” Card. Fail. Rev., vol. 9, no. Icd, 2023, doi: 10.15420/cfr.2023.05.

[9] P. K. Whelton, R. M. Carey, G. Mancia, R. Kreutz, J. D. Bundy, and B. Williams, “Harmonization of the American College of Cardiology/American Heart Association and European Society of Cardiology/European Society of Hypertension Blood Pressure/Hypertension Guidelines: Comparisons, Reflections, and Recommendations,” Circulation, vol. 146, no. 11, pp. 868–877, 2022, doi: 10.1161/CIRCULATIONAHA.121.054602.

[10] M. Jannah, B. Abdul, and M. Syahrul Ningrat, “Pembatasan Caıran Dan Pemberıan Dıuretık Untuk Mengurangı Edema Pada Pasıen Acute Decompensated Heart Faılure (ADHF),” Politek. Kesehat. Makassar, vol. 15, no. 1, pp. 2087–2122, 2024.

[11] Y. Pintaningrum, A. Utamayasa, M. A. Rahman, T. Ontoseno, and K. A. A. P. Pramana, “Peranan ACE-Inhibitor pada penyakit jantung bawaan,” Sasambo J. Pharm., vol. 4, no. 2, pp. 69–76, 2023, doi: 10.29303/sjp.v4i2.240.

[12] C. Caiati, R. Arrigoni, A. Stanca, and M. E. Lepera, “Kidney Toxicity of Drugs for the Heart: An Updated Perspective,” Metabolites, vol. 15, no. 3, 2025, doi: 10.3390/metabo15030191.

[13] WHO, Quality of Life, 03 ed. English: World Health Organization, 2022. doi: 10.4324/9781003217572-6.

[14] A. M. Gallagher, R. Lucas, and M. R. Cowie, “Assessing health-related quality of life in heart failure patients attending an outpatient clinic: a pragmatic approach,” ESC Hear. Fail., vol. 6, pp. 3–9, 2019, doi: 10.1002/ehf2.12363.

[15] S. D. Solomon et al., “Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction,” N. Engl. J. Med., vol. 381, no. 17, pp. 1609–1620, 2019, doi: 10.1056/nejmoa1908655.

[16] Dinas Kesehatan Kota Tasikmala, Profil Kesehatan Kota Tasikmalaya 2023 Dinas Kesehatan Kota Tasikmalaya. 2023.

[17] G. Lippi and F. Sanchis-gomar, “Global epidemiology and future trends of heart failure,” AME Med. J., vol. 5, no. 15, pp. 1–6, 2020, doi: 10.21037/amj.2020.03.03.

[18] K. Kang, Q. Wang, Y. Li, C. Liu, H. Yu, and N. Li, “Global and Chinese perspectives on the growing burden of heart failure : trends , gender , and age-related differences ( 1990 – 2021 ) based on GBD 2021 data,” BMC Cardiovasc. Disord., vol. 25, no. 510, pp. 1–11, 2025.

[19] L. L. Khuzaima and Sunardi, “Hubungan Tingkat Pendidikan terhadao Kepatuhan Minuman Obat Antihipertensi di Puskesmas Sewon II Periode Januari 2021,” AKFARINDO, vol. 6, no. 2, pp. 15–21, 2021.

[20] P. M. C. Simanjuntak, V. F. F. Joseph, and V. G. X. Rooroh, “Hubungan Riwayat Merokok Aktif terhadap Fraksi Ejeksi Ventrikel Kiri pada Pasien Gagal Jantung,” e-Clinic, vol. 14, no. 1, pp. 143–149, 2026.

[21] I. T. Nursyifa and C. Tarigan, “ACE- inhibitor pada HFrEF dan HFpEF,” Indones. Nurs. J. Educ. Clin., vol. 4, no. 1, pp. 13–18, 2024.

[22] D. H. P. Sihombing, N. C. I. Polii, and A. L. Panda, “Penggunaan Mineralocorticoid Receptor Antagonist pada Heart Failure Reduced Ejection Fraction,” e-CliniC, vol. 9, no. 2, pp. 379–387, 2021.

[23] KDIGO, “KDIGO 2024 Clınıcal Practıce Guıdelıne For The Evaluatıon And Management,” Off. J. Int. Soc. Nephrol., vol. 105, no. 4, 2024.

[24] A. Pascayantri, E. Wahyudin, and H. Kasim, “Kajıan Penggunaan Captoprıl Dan Ramıprıl Terhadap Parameter Fungsı Gınjal Pada Pasıen CHF,” Maj. Farm. dan Farmakol., vol. 22, no. 3, pp. 73–75, 2018.

[25] E. F. A. Lestari, Susilowati, and O. D. H, “Evaluasi efektivitas antihipertensi pada pasien hipertensi dengan gagal ginjal kronis di rawat inap rsud kota madiun,” Duta Pharma J., vol. 1, no. 2, pp. 25–31, 2021.

[26] F. S. Irawan and M. Ludong, “Gambaran fungsi ginjal pada lansia Panti Wreda Salam Sejahtera berdasarkan estimated glomerular filtration rate ( eGFR ),” Tarumanagara Med. J., vol. 2, no. 2, pp. 244–251, 2020.

[27] N. Pudiarifanti, Dewa Pramantara, and Z. Ikawati, “Faktor-Faktor Yang Mempengaruhı Kualıtas Hıdup Pasıen Gagal Jantung Kronık,” J. Manaj. dan Pelayanan Farm., vol. 5, no. 4, pp. 259–266, 2020.

[28] Y. Made, P. A. L. Berek, M. F. W. . Fouk, C. Anugrahini, C. Saputra, and M. Alimansur, “Gambaran Karakterıstık Dan Kualıtas Hıdup Pasıen Gagal Jantung Kongestıf Dı RS X, Atambua,” J. Ilmu Kesehat., vol. 13, no. 2, pp. 229–237, 2025.

[29] T. A. McDonagh et al., “European Society of Cardiology (ESC) Guidlines for the Diagnosis and Treatment of Acute and Chronic Heart Failure,” Eur. Soc. Cardiol., vol. 42, pp. 3599–3726, 2021, doi: 10.1093/eurheartj/ehab368.

[30] PERKI, Pedomam Tatalaksana penyakit gagal jantung. Indonesia: Perhimpunan Dokter spesialis Kardiovaskular (PERKI), 2023. [Online]. Available: http://www.nber.org/papers/w16019

[31] H. Nursita and A. Pratiwi, “Peningkatan Kualitas Hidup pada Pasien Gagal Jantung: A Narrative Review Article,” J. Ber. Ilmu Keperawatan, vol. 13, no. 1, pp. 10–21, 2020, doi: 10.23917/bik.v13i1.11916.

[32] B. Żółkowska et al., “Clinical and Psychological Factors Associated with Frailty in Patients with Heart Failure,” J. Clin. Med., vol. 13, no. 7345, pp. 1–13, 2024, doi: 10.3390/jcm13237345.

[33] D. A. Pratama, S. A. Nasution, M. Muhadi, A. Mansjoer, and I. Alwi, “Jurnal Penyakit Dalam Indonesia Faktor-Faktor yang Memengaruhi Kualitas Hidup Pasien Gagal Jantung Kronik Fraksi Ejeksi Terjaga ( HFpEF ) Rawat Jalan di RSUPN Dr. Cipto Mangunkusumo,” J. Penyakit Dalam Indones., vol. 11, no. 1, 2024, doi: 10.7454/jpdi.v11i1.1553.

[34] L. Wu, M. Rodriguez, K. El Hachem, and C. Krittanawong, “Diuretic Treatment in Heart Failure : A Practical Guide for Clinicians,” J. Clin. Med., vol. 13, pp. 1–30, 2024, doi: https://doi.org/10.3390/jcm13154470.